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With the use of Artificial Intelligence, 
Magnetic Resonance Imaging (MRI) 
can characterize brain tumor 
heterogeneity. 
Take a picture to 
download a previously 
published paper on the topic.
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INTRODUCTION:
• 95% of Glioblastoma patients die within five years. Other gliomas are similarly 
fatal with high levels of recurrence after treatment.
• Gliomas are primarily treated by surgical resection followed by chemotherapy and 
radiation. Post-surgical histology reveals relevant mutations in the tumor cells, 
allowing for the selection of specified chemotherapy drugs.
• However, drug effectiveness is limited by tumor heterogeneity.
• Gliomas are not homogenous masses of invasive cells but are heterogenous 
groups of cancer cells with varying mutations. 
• Post-surgical histology is only representative of a small tumor subpopulation, and 
specified drug treatment fails to treat other cell populations. On account of this 
heterogeneity, tumors recur after treatment.
• With improved detection of tumor heterogeneity, oncologists could select more 
specified drug treatments, thereby improving glioma recurrence and survival rates.
• Current biopsy and histology methods fail to adequately detect tumor 
heterogeneity. In the future, MRI imaging coupled with artificial intelligence 
could more effectively detect heterogeneity.
• To further develop this idea, we conducted a retrospective study, analyzing brain 
scans and biopsy samples for ten glioma patients. 
METHODS:
1. Identification of 10 glioma patients from an ongoing neurosurgery study according 
to IRB protocols. Consent was waived on account of the retrospective nature of 
the study. All PHI remained confidential. 
2. Patients included had an MRI scan with at least five series: T1, T2, T2 FLAIR, DWI, 
and T2 with contrast. 
3. During surgical resection of the glioma, stereotactic localization (see center figure) 
of up to four tumor tissue samples was captured each patient. Such localization 
enabled pairing of biopsy location with the corresponding coordinates on the MR 
scan. 
4. Each biopsy sample was sent to CHOP for DNA sequencing, and analysis centered 
on eight gene targets which are commonly mutated in glioma patients.
5. DNA sequencing analysis and MR images were fed into a 3-layer neural network. 
After the neural network was trained via cross validation and the leave-one-out 




• Testing accuracy of 76.5% shows that our neural network can effectively predict 
mutations in tumor subpopulations from MR images.
• Future studies are needed to train the neural network with more patients and 
potentially more mutations.
• We are working to choose mRNA and DNA methylation targets so that our neural 
network can detect changes in expression and methylation patterns.
• We are in the process of obtaining IRB approval for a prospective study which 
includes more patients and uses stereotactic core biopsy, an improvement on the 
stereotactic techniques used in this paper. 
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Patient # of samples (voxels)
Mode of Exons 
Histograms
PAT61 1327 0 1 1 1 0 0 0 0
PAT64 1981 0 1 0 0 0 0 1 0
PAT66 29039 0 1 1 1 0 0 0 0
PAT72 1325 0 0 1 0 0 0 1 0
PAT73 1743 1 0 0 1 0 0 1 0
PAT83 1463 0 1 1 0 0 1 0 0
PAT84 12965 0 1 1 0 0 1 0 0




Mode of Exons: PTEN, IDH1, TP53, EGFR, PIK3R1, 
PIK3CA, NF1, NBI










Standard deviation 0.150253 0.007739
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